BCAL seeks Medicare backing for Avantect pancreatic cancer blood test

BCAL Diagnostics Limited ( (AU:BDX) ) just unveiled an announcement.

BCAL Diagnostics has lodged an application with the Medical Services Advisory Committee seeking Medicare Benefits Schedule reimbursement for its Avantect Pancreatic Cancer Test, aiming to make the blood-based assay more broadly accessible to high-risk patients. The test, launched in Sydney in January 2026, is already being rolled out commercially through Sonic Healthcare in key eastern states and nationally via Healius, with strong early interest from clinicians managing new-onset diabetes.

The company argues that public funding would be a major commercial and clinical inflection point, supporting wider clinician adoption, reduced out-of-pocket costs, and potential integration into standard care for pancreatic cancer risk assessment. Its submission is underpinned by validation data on test performance and backed by advocacy groups such as PanCare Foundation and Pankind, reinforcing the significant unmet need for earlier detection in one of the deadliest cancers.

The most recent analyst rating on (AU:BDX) stock is a Sell with a A$0.09 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.

More about BCAL Diagnostics Limited

BCAL Diagnostics Limited is an Australian healthcare company focused on developing pioneering diagnostics for the early detection of cancer. Its lead product, the Avantect Pancreatic Cancer Test, is a non-invasive blood-based assay targeting high-risk groups such as older patients with new-onset diabetes and individuals with genetic or familial risk factors for pancreatic cancer.

Average Trading Volume: 289,691

Technical Sentiment Signal: Buy

Current Market Cap: A$37.79M

Learn more about BDX stock on TipRanks’ Stock Analysis page.